PPARG and colitis: Previous data from our and other groups have also evidenced that pioglitazone is capable of halting inflammation in mice models of experimental colitis [1,15], and while there is evidence that PPARγ is also an important role player in BBB physiology [24], there are no studies on the anti-inflammatory actions of such ligands on the BBB as well.